Clinical Trial Update: NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial update for NBI-98854 (valbenazine) in tardive dyskinesia in patients with schizophrenia or schizoaffective disorder; results were posted after com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia
• Tardive Dyskinesia

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 2 | Status: COMPLETED | Results posted: 2017-08-10